Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Lipegfilgrastim in Patients with Non-Small Cell Lung Cancer Receiving Myelosuppressive Therapy
SpringerPlus（2015）
Abstract
The aim of this study was to demonstrate lipegfilgrastim superiority versus placebo in adults with non-small cell lung cancer receiving myelosuppressive chemotherapy.
MoreTranslated text
Key words
Neutropenia,Non-small cell lung cancer,Recombinant granulocyte colony-stimulating factor,Lipegfilgrastim,Phase III clinical trial
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined